Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Edaravone

(Synonyms: MCI-186) Copy Product Info
🥰Excellent
Hot

Synonyms: MCI-186

Catalog No. T0407 Copy Product Info
Purity: 99.98%
🥰Excellent
Hot
Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
Edaravone
Cas No. 89-25-8
Pack SizePriceUSA StockGlobal StockQuantity
10 g$30-In Stock
25 g$46-In Stock
1 mL x 10 mM (in DMSO)$29In StockIn Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.98%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
In vitro
Edaravone significantly improves neurological function in animals. Treatment with edaravone substantially reduces TUNEL-positive apoptotic cells and increases the expression of Bcl-2, while decreasing the immunoreactivity of Bax protein in the peri-infarct area. The research demonstrates that edaravone provides excellent protection against ischemic/reperfusion-induced brain injury through a Bcl-2/Bax protein-dependent anti-apoptotic mechanism. Following a 24-hour infusion of edaravone into murine brain tissue, there is a notable reduction in infarct volume and amelioration of neurological deficits. In the early stages post-reperfusion, edaravone significantly inhibits the accumulation of HNE-modified proteins and 8-OHdG in the penumbral region, reduces the expression of iNOS, diminishes microglial activation, and lowers the formation of nitrotyrosine. Edaravone also markedly attenuates renal function and pathological outcomes in rat kidneys, significantly reducing free radical production in renal tubular epithelial cells as indicated by fluorescence.
In vivo
Edaravone optimizes the state of NOS by reducing the detrimental isoforms iNOS and nNOS, while increasing the beneficial eNOS, thus favoring neuroprotection in ischemic stroke. It inhibits oxidation and enhances eNOS expression without boosting production, improving and preserving cerebral blood flow during reperfusion without necessitating peroxynitrite formation. Edaravone exerts its neuroprotective effect by mitigating neuronal damage from cerebral ischemia and inhibiting endothelial injury.
SynonymsMCI-186
Cell Research
Cell viability is quantified by MTT assay and trypan blue staining. MTT (5?mg/mL, 20?μL) is added to each well and incubated for 4?h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570?nm using an ELISA reader.
Chemical Properties
Molecular Weight174.20
FormulaC10H10N2O
Cas No.89-25-8
SmilesCC1=NN(C(=O)C1)C1=CC=CC=C1
Relative Density.1.267 g/cm3. Temperature:20 °C.;1.266 g/cc. Temperature:20 °C.
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 247 mg/mL (1417.91 mM), Sonication is recommended.
In Vivo Formulation
5% DMSO+40% PEG300+5% Tween80+50% Saline: 4 mg/mL (22.96 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM5.7405 mL28.7026 mL57.4053 mL287.0264 mL
5 mM1.1481 mL5.7405 mL11.4811 mL57.4053 mL
10 mM0.5741 mL2.8703 mL5.7405 mL28.7026 mL
20 mM0.2870 mL1.4351 mL2.8703 mL14.3513 mL
50 mM0.1148 mL0.5741 mL1.1481 mL5.7405 mL
100 mM0.0574 mL0.2870 mL0.5741 mL2.8703 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Keywords

Related Tags: Edaravone chemical structure | Edaravone in vivo | Edaravone in vitro | Edaravone formula | Edaravone molecular weight